Welcome to this special edition of Neurology News Network. I am Marco Meglio.
The FDA has given Rafa Laboratories the green light for its 10 mg midazolam auto-injector for the treatment of status epilepticus in adults.1 It is the first auto-injectable product to be approved by the FDA. FDA, joining other rescue treatments with different routes of administration. According to the American Epilepsy Society treatment guidelines, intramuscular injection of midazolam is a first-line treatment for status epilepticus. Similarly, Neurocritical Care Society guidelines state that irreversible brain damage or death can occur if seizures are not stopped within 60 minutes of onset.3 The midazolam auto-injector is administered into the thigh and can be administered through clothing, without requiring an IV line, according to Rafa. The Rafa auto-injector was developed in partnership with the U.S. Department of Defense’s Joint Program for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) Executive Office, with additional support from the Chemical Defense Program and organic. Previously, the government entity collaborated with Rafa on his atropine auto-injector.
Presented at the 2022 World Federation of Interventional and Therapeutic Neuroradiology, new data from the INSIGHT Registry showed that use of Penumbra’s RED Reperfusion Catheters cleared all types of clots in patients with ischemic stroke acute. In addition, results from a sub-analysis of the COMPLETE study (NCT03464565) revealed the efficacy of the Penumbra System in treating tandem lesions in these patients, as well as those considered to be in the last treatment window. The Penumbra System is a fully integrated system designed for effective clot removal and is intended for patients with acute ischemic stroke secondary to intracranial large vessel occlusions. In a cohort of 161 acute ischemic stroke patients from the INSIGHT registry, treatment with Penumbra’s latest reperfusion catheters resulted in successful first-pass revascularization, indicated by altered thrombolysis in cerebral infarction (mTICI) scores between 2b and 3, which occurred in 68.9% of cases. of sick. In total, the results reported by the site showed that 97.0% of patients had successful revascularization after final angiography. Final mTICI scores of at least 2b-3 were reported in 98.1% of patients with firm red clots and in 100% of patients with other types of clots.
Data from a large-scale study of more than 10,000 children aged 9 to 10 showed that smoking initiation was associated with lower cognitive performance and reduced brain structure with lasting effects when smoking. a 2-year follow-up. A total of 11,729 children from 21 US sites enrolled in the Adolescent Brain Cognitive Development (ABCD) study were included in wave 1 from October 2016 to October 2018, and followed 2 years later from August 2018 to January 2021 Participants were asked to complete a survey about their tobacco use, and products such as electronic cigarettes (e-cigarettes), cigarettes, cigars, smokeless tobacco, hookah, pipes and substitutes nicotine. There were 116 children who reported having ever used tobacco products, considered to be the consumer group. This group had lower Picture Vocabulary Test scores, lower crystallized cognition composite scores, and total cognition composite scores. At the 2-year follow-up, tobacco users had lower cortical volume in the frontal, parietal, and temporal lobes than nonusers.
For more direct access to expert information, visit NeurologyLive.com. This was Neurology News Network. Thank you for watching.